$904 Million is the total value of Casdin Capital, LLC's 40 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 57.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLFS | Buy | BIOLIFE SOLUTIONS INC | $107,441,800 | -37.0% | 7,780,000 | +0.8% | 11.89% | -20.3% |
| Buy | STRUCTURE THERAPEUTICS INCsponsored ads | $61,956,632 | +49.5% | 1,258,166 | +26.2% | 6.86% | +89.3% | |
| RLAY | Buy | RELAY THERAPEUTICS INC | $58,227,257 | -22.7% | 6,923,574 | +15.4% | 6.44% | -2.1% |
| VERV | Buy | VERVE THERAPEUTICS INC | $39,179,455 | -11.5% | 2,954,710 | +25.2% | 4.34% | +12.1% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $21,711,480 | +2423.4% | 498,427 | +1993.0% | 2.40% | +3104.0% |
| Buy | TANGO THERAPEUTICS INC | $14,720,750 | +343.4% | 1,307,349 | +30.7% | 1.63% | +461.7% | |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $8,649,423 | – | 1,035,859 | +100.0% | 0.96% | – |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $7,975,000 | -15.4% | 1,250,000 | +47.1% | 0.88% | +7.2% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCcall | $3,542,000 | – | 20,000 | +100.0% | 0.39% | – |
| ILMN | New | ILLUMINA INCcall | $3,432,000 | – | 25,000 | +100.0% | 0.38% | – |
| CDXS | New | CODEXIS INC | $567,000 | – | 300,000 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.